PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis

Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy

(2017) Thomas J Gniadek et al.   MODERN PATHOLOGY

High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma

(2016) Yih-Leong Chang et al.   EUROPEAN JOURNAL OF CANCER

Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies

(2016) Fabien Forest et al.   HUMAN PATHOLOGY

Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations

(2016) Alexa B. Schrock et al.   Journal of Thoracic Oncology

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment

(2016) Tiffany G. Huynh et al.   Journal of Thoracic Oncology

Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases

(2016) Jong-Mu Sun et al.   Journal of Thoracic Oncology

Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma

(2016) V. Gounant et al.   LUNG CANCER

Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages

(2016) Thibault Vieira et al.   LUNG CANCER

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

The impact of immunohistochemistry on the classification of lung tumors

(2016) Giuseppe Pelosi et al.   Expert Review of Respiratory Medicine

Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies

(2015) M. Ilie et al.   ANNALS OF ONCOLOGY

Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas

(2015) Sehui Kim et al.   EUROPEAN JOURNAL OF CANCER

Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers

(2015) Moon-Young Kim et al.   LUNG CANCER

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

(2015) Lars Henning Schmidt et al.   PLoS One

Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)

(2013) Vamsidhar Velcheti et al.   Journal of Thoracic Oncology

p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma

(2011) Justin A Bishop et al.   MODERN PATHOLOGY